You do not have permission to access this chart.
Please Sign Up or Login

Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. Its products include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase Ib clinical trials for the treatment advanced solid tumors and non-Hodgkin’s lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in preclinical stage used in the treatment of cancers; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of metastatic solid tumors. The company was founded in 2011 and is headquartered in Suzhou, China.

Sector:

Healthcare

Industry:

Biotechnology

Address:

Adagene Inc. Building C14 4th Floor No. 218, Xinghu Street Suzhou Industrial Park Suzhou 25125 China

Website:

http://www.adagene.com

Phone:

86 512 8777 3632

Leave a comment

Your email address will not be published. Required fields are marked *